<unk>  in patients on antiplatelet or anticoagulation agents often necessitates reversal of the<unk>  agent. The risk of ongoing<unk>  must be weighed against the risk of precipitating thrombosis in a patient who is anticoagulated.  Protamine is indicated for the treatment of severe<unk>  among patients on heparin.  In case of<unk>  among patients on vitamin K antagonists, oral or intravenous vitamin K and fresh frozen plasma have been used for anticoagulation reversal at the expense of several limitations including time for vitamin K and the need for cross matching and risk of volume overload for fresh frozen plasma.  4 factor prothrombin complex concentrate (PCC) is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adult patients with acute major<unk> .  As for the new oral anticoagulation therapy agents, there are no available antidotes so far and the management for severe<unk>  among patients on these medications is problematic.  The evidence for the use of PCC in case of severe<unk>  among patients on oral anticoagulation therapy is not robust.
Bleeding reversal of anticoagulation and antiplatelet in active bleed
Bleeding perioperative discontinuation, bridging, and reversal of anticoagulation and antiplatelet therapy
Antiplatelet therapy to support PCI
Unstable angina / non ST elevation myocardial infarction factor Xa inhibitors therapy
Heparin-induced thrombocytopenia cost-effectiveness of therapy
Antithrombin III deficiency medical therapy
Heparin-induced thrombocytopenia future or investigational therapies
Glanzmann's thrombasthenia medical therapy